Lineage Cell Therapeutics, Inc. $LCTX

What the company doesAI summary of filing

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic cell replacement therapies for serious medical conditions including geographic atrophy secondary to dry age-related macular degeneration, spinal cord injury, hearing loss, and Type 1 Diabetes. The company manufactures differentiated human cells using its proprietary AlloSCOPE platform, which converts pluripotent stem cells into mature replacement cells that are transplanted to patients to restore lost or dysfunctional cellular function. Its lead program, OpRegen (RG6501), is in Phase 2a development under a worldwide collaboration with Roche and Genentech, under which the company received a $50 million upfront payment and $5 million in development milestone payments, with eligibility for up to $615 million in additional milestone payments plus royalties on net sales. The company is pre-revenue from product sales and currently funds operations through collaboration payments and capital raises. [10-K 2026-03-05]

Segments: OpRegen (RG6501) - RPE cell therapy for geographic atrophy/dry-AMD, OPC1 - oligodendrocyte progenitor cell therapy for spinal cord injury, ReSonance (ANP1) - auditory neuron progenitor cell therapy for hearing loss, ILT1 - islet cell therapy research for Type 1 Diabetes